Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis CEO Sees Recovery Ahead, Fueled By Pipeline And Alcon Growth

Executive Summary

Novartis' half-year results show eye business Alcon and heart drug Entresto - which have been the two main sources of concern - are finally turning around, and its pipeline is firing on all cylinders towards a post-Gleevec recovery.

Advertisement

Related Content

Pharma Q3 Results Preview: Novartis, Lilly, Amgen, GSK
Will Radiopharmaceutical Company AAA Be M&A Fodder For Novartis?
Novartis' Brolucizumab Shows Dose Advantage Over Eylea In nAMD Trials
Can Slow Selling Heart Drug Entresto Perk Up In 2017? Novartis Hopes So

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099154

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel